Libya vs Malaysia: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
Libya
92.0%
in 2025
Malaysia
93.0%
in 2025
Libya rank
56th
Malaysia rank
53rd
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- Libya
- Malaysia
How they compare
Malaysia currently reports 93.0% against 92.0% in Libya, a difference of 1.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Malaysia ahead.
Libya ranks 56th and Malaysia ranks 53rd of 194 countries.
Libya has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Libya | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 44.6% | 0.0% | 44.6% | Libya |
| 2020s | 78.8% | 73.3% | 5.5% | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, Libya or Malaysia?
- Malaysia, at 93.0% against 92.0% in Libya as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between Libya and Malaysia?
- 1.0%, with Malaysia ahead.
- How many years of comparable data are there for Libya and Malaysia?
- 18 years are reported by both, from 2008 to 2025.
- How do Libya and Malaysia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- Libya ranks 56th and Malaysia ranks 53rd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.